Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.49 |
| ▸ | CA2 | P00918 | 12/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28232248 | 0.83 | CA1 (0.54) | CA1CA2HTTSMN1; SMN2CA4 | |
| SCHEMBL10035681 | 0.82 | HTT (0.46) | CA1CA2HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL10067565 | 0.79 | CA1 (0.53) | CA1CA2HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6362947 | 0.79 | CA1 (0.53) | CA1CA2HTTSMN1; SMN2CA4 | |
| SCHEMBL9799462 | 0.79 | CA1 (0.76) | CA1CA2CA4 | |
| SCHEMBL3581670 | 0.78 | CA1 (0.55) | CA1CA2HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL13688773 | 0.77 | SMN1; SMN2 (0.47) | CA1CA2HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL10893116 | 0.76 | CA2 (0.54) | CA1CA2HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL20763946 | 0.76 | HPGD (0.60) | HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28530511 | 0.76 | F2R (0.56) | HTTALDH1A1L3MBTL1F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110329-B2 | Charge controlling agent and toner | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110329-B2 | Charge controlling agent and toner | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20070111125-A1 | CHARGE CONTROLLING AGENT AND TONER | CANON KABUSHIKI KAISHA (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070111125-A1 | CHARGE CONTROLLING AGENT AND TONER | CANON KABUSHIKI KAISHA (JP) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111125-A1 | CHARGE CONTROLLING AGENT AND TONER | CA2, ACTR2, CA12 | CA1 10/4885CA2 1/4885HTT 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.